Programmed Death Ligand 1 (PD-L1) and Tumor-Associated Macrophages in Gastric-Type Hepatocellular Carcinoma: Prognostic Insights
International Journal of Molecular Sciences · 06.07.2026 · 27 (13) · 6048
DOI: 10.3390/ijms27136048 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.07.2026. Verfasst von Rita Szodorai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, B7-H1 Antigen, Tumor-Associated Macrophages. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a heterogeneous primary liver malignancy characterized by limited treatment options and low overall survival rates. Recent studies have explored the role of programmed death ligand 1 (PD-L1), tumor-associated macrophages (TAMs), and epithelial-mesenchymal transition (EMT) in modulating tumor progression and the response to immunotherapy. This study aimed to investigate the association among PD-L1 expression, TAMs, and EMT in HCC, highlighting the recently proposed immunophenotypic variant—gastric-type HCCs. A retrospective cohort of 50 surgically resected HCC patients was analyzed. Immunohistochemical staining was performed for PD-L1 (clones 28-8 and 22C3), CD68 (TAMs), and EMT markers (VSIG-1, TTF-1, and vimentin). PD-L1 expression was detected in 52% of the patients and was significantly associated with high TAM counts (p < 0.001). Compared with PD-L1-negative patients, those with gastric-type HCCs, which are characterized by VSIG-1 and TTF-1 co-expression and vimentin negativity, demonstrated improved survival outcomes (p = 0.03). Integration of immune and EMT profiling of tumor cells in routine diagnostics may guide prognosis and immunotherapeutic strategies in HCC. Further molecular validation is required to confirm the biological significance of the proposed gastric-type HCC immunophenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania.
- Department of Pathology, Clinical County Emergency Hospital, 540136 Targu Mures, Romania.
- Department of Pathology and Experimental Cancer Research, Semmelweis University, 26. Ulloi ut, H-1085 Budapest, Hungary.
- Research Center of Oncopathology and Translational Research (CCOMT), 540136 Targu Mures, Romania.
- Romanian Academy of Medical Sciences, 030167 Bucuresti, Romania.
ORCID-Profile: Ilona Kovalszky, Simona Gurzu
Zitieren
APA
Szodorai, R., Kovalszky, I., Dezső, K., & Gurzu, S. (2026). Programmed Death Ligand 1 (PD-L1) and Tumor-Associated Macrophages in Gastric-Type Hepatocellular Carcinoma: Prognostic Insights. International Journal of Molecular Sciences, 27(13), 6048. https://doi.org/10.3390/ijms27136048
Vancouver
Szodorai R, Kovalszky I, Dezső K, Gurzu S. Programmed Death Ligand 1 (PD-L1) and Tumor-Associated Macrophages in Gastric-Type Hepatocellular Carcinoma: Prognostic Insights. International Journal of Molecular Sciences. 2026;27(13):6048. doi:10.3390/ijms27136048
BibTeX
@article{Szodorai2026,
author = {Szodorai, Rita and Kovalszky, Ilona and Dezső, Katalin and Gurzu, Simona},
title = {Programmed Death Ligand 1 (PD-L1) and Tumor-Associated Macrophages in Gastric-Type Hepatocellular Carcinoma: Prognostic Insights},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {13},
pages = {6048},
doi = {10.3390/ijms27136048}
}
EUVIMED